Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7456009 | 0.95 | CTSL (0.47) | CTSLCTSSSIRT2SIRT1CTSB | |
| SCHEMBL7468905 | 0.89 | CTSK (0.53) | CTSLCTSSCTSB | |
| SCHEMBL7461883 | 0.86 | CTSB (0.43) | CTSLCTSSCTSBHDAC1 | |
| SCHEMBL7466038 | 0.86 | CTSS (0.43) | CTSLCTSSCTSBHDAC1 | |
| SCHEMBL7615379 | 0.86 | CA1 (0.47) | CTSLCTSSCTSB | |
| SCHEMBL7468803 | 0.85 | CTSB (0.53) | CTSLCTSSCTSB | |
| SCHEMBL7464299 | 0.83 | CTSS (0.51) | CTSLCTSSCTSB | |
| SCHEMBL7471992 | 0.83 | CTSL (0.49) | CTSLCTSSSIRT2CTSB | |
| SCHEMBL7464381 | 0.82 | CTSL (0.47) | CTSLCTSSCTSBHDAC1 | |
| SCHEMBL7469098 | 0.79 | CTSS (0.45) | CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSL 4/4885CTSS 10/4885SIRT2 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.